In previous clinical trials of gastric cancer, some EGFR-targeting agents, such as panitumumab, cetuximab and nimotuzumab, have been tested without success.34 These studies were basically undertaken in unselected gastric cancer patients or in patients with EGFR-overexpressing gastric tumours. This evidence concerns the gene EGFR and gastric neoplasm.